Sign In
Buy CVKD
$4.19
-0.160 (-3.68%)
At Close: Jun 03, 2026
Cadrenal Therapeutics to Present at Upcoming Investor Conferences
09:00am, Wednesday, 14'th Aug 2024
PONTE VEDRA, Fla. , Aug. 14, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VK
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update
04:05pm, Wednesday, 07'th Aug 2024
PONTE VEDRA, Fla. , Aug. 7, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA
Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs
09:00am, Tuesday, 06'th Aug 2024
PONTE VEDRA, Fla., Aug. 6, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA
Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
09:00am, Wednesday, 17'th Jul 2024
PONTE VEDRA, Fla. , July 17, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA
Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024
04:15pm, Tuesday, 11'th Jun 2024
PONTE VEDRA, Fla. , June 11, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VK
Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, has t
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
09:00am, Thursday, 23'rd May 2024
PONTE VEDRA, Fla. , May 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (b
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update
09:00am, Thursday, 09'th May 2024
PONTE VEDRA, Fla., May 9, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (bl
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
04:30pm, Thursday, 11'th Apr 2024
PONTE VEDRA, Fla. , April 11, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulan
FDA designation provides potentially seven years of market exclusivity after approval and expanded partnering opportunities for tecarfarin PONTE VEDRA, Fla. , April 9, 2024 /PRNewswire/ -- Cadrenal
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update
09:00am, Monday, 11'th Mar 2024
PONTE VEDRA, Fla., March 11, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
09:00am, Monday, 26'th Feb 2024
PONTE VEDRA, Fla. , Feb. 26, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
09:00am, Thursday, 08'th Feb 2024
PONTE VEDRA, Fla. , Feb. 8, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in an
PONTE VEDRA, Fla. , Jan. 31, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in
Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
09:00am, Wednesday, 24'th Jan 2024
PONTE VEDRA, Fla. , Jan. 24, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (
